Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SETICC: Genotype-guided Treatment in Colorectal Cancer
NCT01071655Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Feb 2010
- Primary completion
- Nov 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, fluorouracil, oxaliplatin and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-Free Survival up to 4 years. Started Feb 2010; status: completed.
02
Drugs
capecitabinefluorouraciloxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01071655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071655.